ArticleBMC infectious diseases2015
Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study.
Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06211985 (Copeptın as a Dısease Severıty Indıcator), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Copeptın as a Dısease Severıty Indıcator: A Prospectıve Case-Control Study
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Diagnostic value of mid-regional pro-Adrenomedullin as a biomarker of invasive bacterial infection in children: a systematic review.BMC pediatrics · 2022Pooled it
- The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections.PloS one · 2022Trial
- Mid-regional pro-adrenomedullin: A rapid sepsis biomarker for diagnosing spontaneous bacterial peritonitis in cirrhosis.European journal of clinical investigation · 2025Article
- Diagnostic and Prognostic Performance of Proadrenomedullin Versus Procalcitonin in Children with Cancer and Febrile Neutropenia.Indian pediatrics · 2025Article
- Research progress of biomarkers in evaluating the severity and prognostic value of severe pneumonia in children.Frontiers in pediatrics · 2024Review
- Red cell distribution width as a prognostic marker for complications of community-acquired pneumonia in children: a comparison with Proadrenomedullin and Copeptin.BMC pulmonary medicine · 2023Article
- Mid-Regional Proadrenomedullin Levels in Primary Immunodeficiencies Complicated with Pulmonary Manifestations.Indian journal of clinical biochemistry : IJCB · 2023Article
- Kinetics and Role of Pancreatic Stone Protein and Midregional Proadrenomedullin as Predictors of Sepsis and Bacteremia in Children with Hematological Malignancies.Mediterranean journal of hematology and infectious diseases · 2023Article
- Association of Serum Albumin and Copeptin with Early Clinical Deterioration and Instability in Community-Acquired Pneumonia.Advances in respiratory medicine · 2022Article
- A Review of Adrenomedullin in Pediatric Patients: A Useful Biomarker.Children (Basel, Switzerland) · 2022Review
- Implications of Using Host Response-Based Molecular Diagnostics on the Management of Bacterial and Viral Infections: A Review.Frontiers in medicine · 2022Review
- Proadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Differential Markers of Bacterial and Viral Infections in Children for Point-of-Care Testing.Trends in molecular medicine · 2020Review
- The Effect of lnterleukin-6 Gene Polymorphism on Pediatric Pneumonia.Iranian journal of public health · 2019Article
- Is copeptin a reliable biomarker of primary monosymptomatic nocturnal enuresis?Central-European journal of immunology · 2019Article
- Point-of-care testing for procalcitonin in identifying bacterial infections in young infants: a diagnostic accuracy study.BMC pediatrics · 2018Observational
- Biomarkers in Pediatric Community-Acquired Pneumonia.International journal of molecular sciences · 2017Review
- Novel biomarkers for cardiovascular risk prediction.Journal of geriatric cardiology : JGC · 2017Review
- Prognostic scores and biomarkers for pediatric community-acquired pneumonia: how far have we come?Pediatric health, medicine and therapeutics · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommunity-acquired-pneumonia is the leading cause of child mortality worldwide. Very few studies have explored the predictive value of Proadrenomedullin and Copeptin in pediatric severe pneumonia and bacteremia.
methodsProadrenomedullin and Copeptin were assessed as predictors for complicated community-acquired pneumonia (bacteremia, empyema) in 88 children aged 0 to 16 years presenting to the pediatric emergency department, using B.R.A.H.M.S. Kryptor Compact pro-ADM and Copeptin with the TRACE technology (time-resolved amplified cryptase emission). STARD standard reporting was used.
resultsA complicated community-acquired pneumonia was found in 11 out of 88 children (12.5 %). Proadrenomedullin median values increased more than twofold, in complicated vs. uncomplicated (0.18 vs. 0.08 nmol/L, p = 0.039), and fivefold in bacteremic vs. non-bacteremic pneumonia (0.40 vs. 0.08 nmol/L, p = 0.02). Proadrenomedullin > 0.16 nmol/L showed 100 % sensitivity (95 % CI 39.8 - 100.0) and 70 % (95 % CI 58.7 - 79.7) specificity for bacteremia. Copeptin showed no added-value.
conclusionsProadrenomedullin seems a reliable and available predictor for complicated CAP, and could therefore help the physician with the decision to hospitalize, and choose the antibiotics administration route. Larger studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.